# Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis

> **NCT00633191** · PHASE1,PHASE2 · COMPLETED · sponsor: **Immunsystem AB** · enrollment: 14 (actual)

## Conditions studied

- Cystic Fibrosis
- Infection
- Pseudomonas Aeruginosa

## Interventions

- **DRUG:** Anti-pseudomonas IgY gargle

## Key facts

- **NCT ID:** NCT00633191
- **Lead sponsor:** Immunsystem AB
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633191, "Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00633191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*